Showing results (291-300 of 322) with videos related to

Sort By:
Pageof 33
BMJ Open|January 24, 2023
How to increase value and reduce waste in research: initial experiences of applying Lean thinking and visual management in research leadershipMalene Grubbe Hildebrandt, Kristian Kidholm, Jørgen Ejler Pedersen, et al.
Nature Communications|March 8, 2018
Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cellsAlexei F Kirkin, Karine N Dzhandzhugazyan, Per Guldberg, et al.
JAMA Oncology|December 4, 2015
The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer RecurrenceMichail Ignatiadis, Hatem A Azim, Christine Desmedt, et al.
BMC Genomics|June 10, 2016
The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cellsStine Ninel Hansen, Natasja Spring Ehlers, Shida Zhu, et al.
Nature Communications|October 28, 2015
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxelZhen Ning Wee, Siti Maryam J M Yatim, Vera K Kohlbauer, et al.
Nature Communications|September 6, 2017
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancerKirstine Jacobsen, Jordi Bertran-Alamillo, Miguel Angel Molina, et al.
Nature Communications|July 15, 2022
Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapyShijun Ma, Yue Zhao, Wee Chyan Lee, et al.
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialMeredith M Regan, Brian Leyland-Jones, Mark Bouzyk, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 25, 2022
IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancerLi-Teng Ong, Wee Chyan Lee, Shijun Ma, et al.
NPJ Breast Cancer|January 5, 2021
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefitSanne Løkkegaard, Daniel Elias, Carla L Alves, et al.
Pageof 33